ACBI2

立即咨询

ACBI2

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

ACBI2 是一种高效且具有口服活性的VHL PROTAC(EC₅₀: 7 nM)，可降解SMARCA2(RKO 细胞中DC₅₀: 1 nM)。ACBI2 可用于肺癌的研究。

生物活性

ACBI2 is a highly potent and orally activeVHLPROTAC(EC₅₀: 7 nM), which selectively degradesSMARCA2with aDC₅₀value of 1 nM in RKO cells. ACBI2 can be used in the research of lungcancer^[1].

IC₅₀& Target^[1]

VHL

7 nM (EC₅₀)

SMARCA2

体外研究
(In Vitro)

ACBI2 (0.1 nM-1 μM, 4-18 h) rapidly and completely degrades SMARCA2 in two sensitive cell lines (A549 and NCI-H1568)^[1].
ACBI2 (1 nM-1 μM, 18 h) significantly degrades SMARCA2 with clear selectivity over SMARCA4^[1].

体内研究
(In Vivo)

ACBI2 (80 mg/kg, p.o., once daily) significantly inhibits tumor growth in an A549 xenograft mice model^[1].
ACBI2 (5-100 mg/kg, p.o., tumors collected 24 or 48 h after treatment) dose-dependently degrades SMARCA2 in NCI-H1568 and A549 engrafted tumor bearing mice (IHC staining)^[1].
ACBI2 (30 mg/kg, p.o., mice) shows oral bioavailability of 22%^[1].

Animal Model:	A549 xenograft mice model^[1]
Dosage:	80 mg/kg
Administration:	Oral administration (p.o.), once daily
Result:	Inhibited tumor growth and was well tolerated.

分子量

1063.17

Formula

C₅₇H₆₉BrFN₇O₅S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.